Sold as Temaril. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Trimeprazine Tartrate (sold as Temaril), with 0 new uses approved and 0 published complete response letters.
| — | Trimeprazine TartrateANDA 85015 | Alpharma US Pharms | 0 | Discontinued |
| — | Trimeprazine TartrateANDA 88285 | Morton Grove | 0 | Discontinued |
| — | TemarilNDA 11316 | Allergan Herbert | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
